Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAFIR-IMPACT BTC: Precision Medicine in Adjuvant Biliary Tract Cancer
NCT07745296Phase 3Not yet recruiting
- Sponsor
- Unicancer
- Start
- Jan 2027
- Primary completion
- Jul 2033
01
Overview
A Phase 3 trial of futibatinib, ivosidenib, zanidatamab in biliary tract cancer (BTC), sponsored by Unicancer. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
futibatinibivosidenibzanidatamab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07745296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07745296.